Tags

Type your tag names separated by a space and hit enter

Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
World J Gastroenterol 2015; 21(13):3777-85WJ

Abstract

Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is considered to be a hepatic manifestation of metabolic syndrome, and its incidence is rapidly increasing worldwide. It is currently the most common chronic liver disease. NASH can progress to liver cirrhosis and hepatocellular carcinoma, and may result in liver-related death. Currently, the principal treatment for NAFLD/NASH is lifestyle modification by diet and exercise. However, pharmacological therapy is indispensable because obese patients with NAFLD often have difficulty maintaining improved lifestyles. The pathogenesis of NAFLD/NASH has not been completely elucidated. However, insulin resistance, inflammatory cytokines, and oxidative stress are thought to be important in the development and/or progression of the disease. Currently, insulin sensitizers (thiazolidinediones) and antioxidants (vitamin E) seem to be the most promising therapeutic agents for NAFLD/NASH, and lipid-lowering drugs, pentoxifylline, angiotensin receptor blockers, and n-3 polyunsaturated fatty acids also have promise. However, there is a lack of consensus regarding the most effective and appropriate pharmacotherapy for NAFLD/NASH. Animal experiments suggest that herbal medicines and natural products may be promising therapeutic agents for NAFLD/NASH, but their efficacy and safety are yet to be investigated in human studies. In this paper, we review the existing and potential pharmacological therapies for NAFLD/NASH.

Authors+Show Affiliations

Yoshihisa Takahashi, Toshio Fukusato, Department of Pathology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.Yoshihisa Takahashi, Toshio Fukusato, Department of Pathology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.Yoshihisa Takahashi, Toshio Fukusato, Department of Pathology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.Yoshihisa Takahashi, Toshio Fukusato, Department of Pathology, Teikyo University School of Medicine, Tokyo 173-8605, Japan.

Pub Type(s)

Editorial
Review

Language

eng

PubMed ID

25852263

Citation

Takahashi, Yoshihisa, et al. "Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease/nonalcoholic Steatohepatitis." World Journal of Gastroenterology, vol. 21, no. 13, 2015, pp. 3777-85.
Takahashi Y, Sugimoto K, Inui H, et al. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World J Gastroenterol. 2015;21(13):3777-85.
Takahashi, Y., Sugimoto, K., Inui, H., & Fukusato, T. (2015). Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. World Journal of Gastroenterology, 21(13), pp. 3777-85. doi:10.3748/wjg.v21.i13.3777.
Takahashi Y, et al. Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease/nonalcoholic Steatohepatitis. World J Gastroenterol. 2015 Apr 7;21(13):3777-85. PubMed PMID: 25852263.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. AU - Takahashi,Yoshihisa, AU - Sugimoto,Keiichiro, AU - Inui,Hiroshi, AU - Fukusato,Toshio, PY - 2014/11/25/received PY - 2015/01/08/revised PY - 2015/02/05/accepted PY - 2015/4/9/entrez PY - 2015/4/9/pubmed PY - 2016/1/21/medline KW - Nonalcoholic fatty liver disease KW - Nonalcoholic steatohepatitis KW - Pharmacological therapy KW - Thiazolidinedione KW - Vitamin E SP - 3777 EP - 85 JF - World journal of gastroenterology JO - World J. Gastroenterol. VL - 21 IS - 13 N2 - Nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) is considered to be a hepatic manifestation of metabolic syndrome, and its incidence is rapidly increasing worldwide. It is currently the most common chronic liver disease. NASH can progress to liver cirrhosis and hepatocellular carcinoma, and may result in liver-related death. Currently, the principal treatment for NAFLD/NASH is lifestyle modification by diet and exercise. However, pharmacological therapy is indispensable because obese patients with NAFLD often have difficulty maintaining improved lifestyles. The pathogenesis of NAFLD/NASH has not been completely elucidated. However, insulin resistance, inflammatory cytokines, and oxidative stress are thought to be important in the development and/or progression of the disease. Currently, insulin sensitizers (thiazolidinediones) and antioxidants (vitamin E) seem to be the most promising therapeutic agents for NAFLD/NASH, and lipid-lowering drugs, pentoxifylline, angiotensin receptor blockers, and n-3 polyunsaturated fatty acids also have promise. However, there is a lack of consensus regarding the most effective and appropriate pharmacotherapy for NAFLD/NASH. Animal experiments suggest that herbal medicines and natural products may be promising therapeutic agents for NAFLD/NASH, but their efficacy and safety are yet to be investigated in human studies. In this paper, we review the existing and potential pharmacological therapies for NAFLD/NASH. SN - 2219-2840 UR - https://www.unboundmedicine.com/medline/citation/25852263/Current_pharmacological_therapies_for_nonalcoholic_fatty_liver_disease/nonalcoholic_steatohepatitis_ L2 - http://www.wjgnet.com/1007-9327/full/v21/i13/3777.htm DB - PRIME DP - Unbound Medicine ER -